GENOME EDITING OF IMMUNODEFICIENCY GENES IN ANIMALS
The present invention provides genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins. In particular, the animals or cells are generated using a zinc finger nuclease-mediated editing process. Also provided are methods of assessing the effects of agents in genetically modified animals and cells comprising edited chromosomal sequences encoding immunodeficiency proteins.
1 . A genetically modified animal comprising at least one edited chromosomal sequence encoding an immunodeficiency protein.
2 . The genetically modified animal of claim 1 , wherein the edited chromosomal sequence is inactivated, modified, or comprises an integrated sequence.
3 . The genetically modified animal of claim 1 , wherein the edited chromosomal sequence is inactivated such that no functional immunodeficiency-associated protein is produced.
4 . The genetically modified animal of claim 3 , wherein the inactivated chromosomal sequence comprises no exogenously introduced sequence.
5 . The genetically modified animal of claim 3 , further comprising at least one chromosomally integrated sequence encoding a functional immunodeficiency protein.
6 . The genetically modified animal of claim 1 , wherein the immunodeficiency protein is chosen from RAG1, RAG2, DNAPK AND FOXN1 and combinations thereof.
7 . The genetically modified animal of claim 1 , further comprising a conditional knock-out system for conditional expression of the immunodeficiency protein.
8 . The genetically modified animal of claim 1 , wherein the edited chromosomal sequence comprises an integrated reporter sequence.
9 . The genetically modified animal of claim 1 , wherein the animal is heterozygous or homozygous for the at least one edited chromosomal sequence.
10 . The genetically modified animal of claim 1 , wherein the animal is an embryo, a juvenile, or an adult.
11 . The genetically modified animal of claim 1 , wherein the animal is chosen from bovine, canine, equine, feline, ovine, porcine, non-human primate, and rodent.
12 . The genetically modified animal of claim 1 , wherein the animal is rat.
13 . The genetically modified animal of claim 12 , wherein the animal is rat and the protein is an ortholog of a human immunodeficiency protein.
14 . A non-human embryo, the embryo comprising at least one RNA molecule encoding a zinc finger nuclease that recognizes a chromosomal sequence encoding an immunodeficiency protein, and, optionally, at least one donor polynucleotide comprising a sequence encoding an immunodeficiency protein.
15 . The non-human embryo of claim 14 , wherein the immunodeficiency protein is chosen from RAG1, RAG2, DNAPK AND FOXN1, and combinations thereof; and the embryo is chosen from bovine, canine, equine, feline, ovine, porcine, non-human primate, and rodent.
16 . The non-human embryo of claim 15 , wherein the zinc finger nuclease comprises a DNA binding domain that binds a sequence having at least about 80% sequence identity to a sequence chosen from SEQ ID NOS: 5, 6, 7, 8, 9, 10, 11, 12, 13, and 14.
17 . The non-human embryo of claim 15 , wherein the embryo is rat and the protein is an ortholog of the human immunodeficiency protein.
18 . A genetically modified cell, the cell comprising at least one edited chromosomal sequence encoding an immunodeficiency protein.
19 . The genetically modified cell of claim 18 , wherein the edited chromosomal sequence is inactivated, modified, or comprises an integrated sequence.
20 . The genetically modified cell of claim 18 , wherein the edited chromosomal sequence is inactivated such that no functional immunodeficiency-associated protein is produced.
21 . The genetically modified cell of claim 20 , wherein the inactivated chromosomal sequence comprises no exogenously introduced sequence.
22 . The genetically modified animal of claim 20 , further comprising at least one chromosomally integrated sequence encoding a functional immunodeficiency protein.
23 . The genetically modified cell of claim 18 , wherein the immunodeficiency protein is chosen from RAG1, RAG2, DNAPK AND FOXN1 and combinations thereof.
24 . The genetically modified cell of claim 18 , further comprising a conditional knock-out system for conditional expression of the immunodeficiency protein.
25 . The genetically modified cell of claim 18 , wherein the edited chromosomal sequence comprises an integrated reporter sequence.
26 . The genetically modified cell of claim 18 , wherein the immunodeficiency protein is chosen from RAG1, RAG2, DNAPK AND FOXN1, and combinations thereof; and the cell is of bovine, canine, equine, feline, human, ovine, porcine, non-human primate, or rodent origin.
27 . The genetically modified cell of claim 19 , wherein the cell is heterozygous or homozygous for the at least one edited chromosomal sequence.
28 . The genetically modified cell of claim 19 , wherein the cell is of rat origin and the protein is an ortholog of a human immunodeficiency protein.
29 . A method for assessing the effect of an agent in an animal, the method comprising contacting a genetically modified animal comprising at least one edited chromosomal sequence encoding an immunodeficiency protein with an agent, and comparing results of a selected parameter to results obtained from contacting a wild-type animal with the same agent, wherein the selected parameter is chosen from:
a) rate of elimination of the agent or its metabolite(s);
b) circulatory levels of the agent or its metabolite(s);
c) bioavailability of the agent or its metabolite(s);
d) rate of metabolism of the agent or its metabolite(s);
e) rate of clearance of the agent or its metabolite(s);
f) toxicity of the agent or its metabolite(s); and
g) efficacy of the agent or its metabolite(s).
30 . The method of claim 29 , wherein the agent is a pharmaceutically active ingredient, a drug, a toxin, or a chemical.
31 . The method of claim 29 , wherein the at least one edited chromosomal sequence is inactivated such that the immunodeficiency protein is not produced, and wherein the animal further comprises at least one chromosomally integrated sequence encoding an ortholog of the immunodeficiency protein.
32 . The method of claim 29 , wherein the immunodeficiency protein is chosen from RAG1, RAG2, DNAPK AND FOXN1, and combinations thereof.
33 . The method of claim 29 , wherein the animal is a rat of a strain chosen from Dahl Salt-Sensitive, Fischer 344, Lewis, Long Evans Hooded, Sprague-Dawley, and Wistar.
34 . A method for assessing the therapeutic potential of an agent in an animal, the method comprising contacting a genetically modified animal comprising at least one edited chromosomal sequence encoding an immunodeficiency protein with an agent and comparing results of a selected parameter to results obtained from a wild-type animal with no contact with the same agent, wherein the selected parameter is chosen from:
a) spontaneous behaviors;
b) performance during behavioral testing;
c) physiological anomalies;
d) abnormalities in tissues or cells;
e) biochemical function; and
f) molecular structures.
35 . The method of claim 34 , wherein the agent is a pharmaceutically active ingredient, a drug, a toxin, or a chemical.
36 . The method of claim 34 , wherein the at least one edited chromosomal sequence is inactivated such that the immunodeficiency protein is not produced, and wherein the animal further comprises at least one chromosomally integrated sequence encoding an ortholog of the immunodeficiency protein.
37 . The method of claim 34 , wherein the immunodeficiency protein is chosen from RAG1, RAG2, DNAPK AND FOXN1, and combinations thereof.
38 . The method of claim 34 , wherein the animal is a rat chosen from Dahl Salt-Sensitive, Fischer 344, Lewis, Long Evans Hooded, Sprague-Dawley, and Wistar.